| CYTARABINE; DAUNORUBICIN | None | ||
| 100MG;44MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. | |||
|
Yes
| |||
| VYXEOS | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||
| ************ *** ******** ** **** ************ | ************ *** ******** ** **** ************ | ********* ************ ** ************* ****** *** ******** ******* | ********* ************ ** ************* ****** *** ******** ******* | ***** **** ****** *** ********* ** ************* ******* *** ************* ********* | ***** **** ****** *** ********* ** ************* ******* *** ************* ********* | ***** ******* ************ **** ******** ***** ********* | ************ *** ******** ** **** ************ | ************ *** ******** ** **** ************ | ****** ** ************ ********* | ****** ** ************ ********* | ****** ** ************ ********* | ****** ** ************ ********* | ****** ** ************ ********* | ****** ** ************ ********* | ********* ************ ** ************* ****** *** ******** ******* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|